{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:41:43Z","timestamp":1768779703862,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1038\/ncpcardio0914","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T12:32:29Z","timestamp":1182515549000},"page":"368-378","source":"Crossref","is-referenced-by-count":14,"title":["Drug Insight: aldosterone-receptor antagonists in heart failure\u2014the journey continues"],"prefix":"10.1038","volume":"4","author":[{"given":"Srinivasa R","family":"Kalidindi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WH Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpcardio0914_CR1","first-page":"e69","volume":"115","author":"W Rosamond","year":"2006","unstructured":"Rosamond W  et al. (2006) Heart disease and stroke statistics\u20142007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR2","doi-asserted-by":"crossref","unstructured":"The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429\u20131435","DOI":"10.1056\/NEJM198706043162301"},{"key":"BFncpcardio0914_CR3","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293\u2013302","DOI":"10.1056\/NEJM199108013250501"},{"key":"BFncpcardio0914_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M  et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349\u20131355","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR5","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K  et al. (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82: 1730\u20131736","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT and Brilla CG (1991) Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849\u20131865","journal-title":"Circulation"},{"issue":"Suppl 2","key":"BFncpcardio0914_CR7","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1007\/BF00795367","volume":"91","author":"A Wilke","year":"1996","unstructured":"Wilke A  et al. (1996) Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 91 (Suppl 2): S79\u2013S84","journal-title":"Basic Res Cardiol"},{"key":"BFncpcardio0914_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP  et al. (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039\u20131045","journal-title":"Hypertension"},{"key":"BFncpcardio0914_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P  et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243\u20131248","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R Rocha","year":"2001","unstructured":"Rocha R and Stier CT Jr (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308\u2013314","journal-title":"Trends Endocrinol Metab"},{"key":"BFncpcardio0914_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","volume":"10","author":"J Blacher","year":"1997","unstructured":"Blacher J  et al. (1997) Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 10: 1326\u20131334","journal-title":"Am J Hypertens"},{"key":"BFncpcardio0914_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","volume":"19","author":"DA Duprez","year":"1998","unstructured":"Duprez DA  et al. (1998) Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19: 1371\u20131376","journal-title":"Eur Heart J"},{"key":"BFncpcardio0914_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1161\/01.HYP.0000176236.55322.18","volume":"46","author":"MK Rude","year":"2005","unstructured":"Rude MK  et al. (2005) Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46: 555\u2013561","journal-title":"Hypertension"},{"key":"BFncpcardio0914_CR14","first-page":"597","volume":"17","author":"M Iglarz","year":"2004","unstructured":"Iglarz M  et al. (2004) Involvement of oxidative stress in the profibrotic action of aldosterone: interaction with the renin-angiotension system. Am J Hypertens 17: 597\u2013603","journal-title":"Am J Hypertens"},{"key":"BFncpcardio0914_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","volume":"16","author":"A Sato","year":"2003","unstructured":"Sato A and Saruta T (2003) Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16: 781\u2013788","journal-title":"Am J Hypertens"},{"key":"BFncpcardio0914_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/147323000102900103","volume":"29","author":"A Sato","year":"2001","unstructured":"Sato A and Saruta T (2001) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29: 13\u201321","journal-title":"J Int Med Res"},{"key":"BFncpcardio0914_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/01.CIR.0000091234.45664.62","volume":"108","author":"JN Cohn","year":"2003","unstructured":"Cohn JN  et al. (2003) Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 108: 1306\u20131309","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS  et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056\u20131064","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","volume":"39","author":"WH Tang","year":"2002","unstructured":"Tang WH  et al. (2002) Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 39: 70\u201378","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J  et al. (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91: 457\u2013465","journal-title":"J Endocrinol"},{"key":"BFncpcardio0914_CR21","first-page":"1110","volume":"304","author":"J Staessen","year":"1981","unstructured":"Staessen J  et al. (1981) Rise of plasma aldosterone during long-term captopril treatment. N Engl J Med 304: 1110","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00877755","volume":"9","author":"B Pitt","year":"1995","unstructured":"Pitt B (1995) \u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9: 145\u2013149","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFncpcardio0914_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","volume":"89","author":"M Cicoira","year":"2002","unstructured":"Cicoira M  et al. (2002) Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89: 403\u2013407","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"MacFadyen RJ  et al. (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82: 57\u201361","journal-title":"Heart"},{"key":"BFncpcardio0914_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B  et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B  et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309\u20131321","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"B Pitt","year":"2005","unstructured":"Pitt B  et al. (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46: 425\u2013431","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","volume":"110","author":"E Perrier","year":"2004","unstructured":"Perrier E  et al. (2004) Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110: 776\u2013783","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR29","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi M  et al. (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107: 2559\u20132565","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR30","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa041489","volume":"351","author":"SH Hohnloser","year":"2004","unstructured":"Hohnloser SH  et al. (2004) Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351: 2481\u20132488","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR31","first-page":"261","volume":"53","author":"S Degre","year":"1998","unstructured":"Degre S  et al. (1998) Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol 53: 261\u2013267","journal-title":"Acta Cardiol"},{"key":"BFncpcardio0914_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1291\/hypres.22.17","volume":"22","author":"A Sato","year":"1999","unstructured":"Sato A  et al. (1999) Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 22: 17\u201322","journal-title":"Hypertens Res"},{"key":"BFncpcardio0914_CR33","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B  et al. (2003) Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831\u20131838","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cardiores.2005.03.001","volume":"67","author":"D Fraccarollo","year":"2005","unstructured":"Fraccarollo D  et al. (2005) Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 67: 97\u2013105","journal-title":"Cardiovasc Res"},{"key":"BFncpcardio0914_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS  et al. (1995) Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76: 1259\u20131265","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR36","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0735-1097(01)01243-8","volume":"37","author":"KM Yee","year":"2001","unstructured":"Yee KM  et al. (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37: 1800\u20131807","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen RJ  et al. (1997) Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35: 30\u201334","journal-title":"Cardiovasc Res"},{"key":"BFncpcardio0914_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","volume":"85","author":"FJ Ramires","year":"2000","unstructured":"Ramires FJ  et al. (2000) Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 85: 1207\u20131211","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR39","doi-asserted-by":"publisher","first-page":"4E","DOI":"10.1016\/0002-9149(90)90244-U","volume":"65","author":"M Schulman","year":"1990","unstructured":"Schulman M and Narins RG (1990) Hypokalemia and cardiovascular disease. Am J Cardiol 65: 4E\u20139E","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1161\/01.HYP.2.5.672","volume":"2","author":"B Schersten","year":"1980","unstructured":"Schersten B  et al. (1980) Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension 2: 672\u2013679","journal-title":"Hypertension"},{"key":"BFncpcardio0914_CR41","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"ED Burgess","year":"2003","unstructured":"Burgess ED  et al. (2003) Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 25: 2388\u20132404","journal-title":"Clin Ther"},{"key":"BFncpcardio0914_CR42","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1161\/01.CIR.102.19.2325","volume":"102","author":"J Bauersachs","year":"2000","unstructured":"Bauersachs J  et al. (2000) Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 102: 2325\u20132328","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA and Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594\u2013597","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR44","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S  et al. (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212\u20132216","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J  et al. (2002) Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39: 351\u2013358","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR46","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1161\/01.RES.0000102404.81461.25","volume":"93","author":"RA Ahokas","year":"2003","unstructured":"Ahokas RA  et al. (2003) Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 93: e124\u2013e135","journal-title":"Circ Res"},{"key":"BFncpcardio0914_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","volume":"41","author":"B Bozkurt","year":"2003","unstructured":"Bozkurt B  et al. (2003) Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41: 211\u2013214","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","volume":"112","author":"FA Masoudi","year":"2005","unstructured":"Masoudi FA  et al. (2005) Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 112: 39\u201347","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN  et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543\u2013551","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","volume":"46","author":"KB Shah","year":"2005","unstructured":"Shah KB  et al. (2005) The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46: 845\u2013849","journal-title":"J Am Coll Cardiol"},{"key":"BFncpcardio0914_CR51","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.553370","volume":"112","author":"SA Hunt","year":"2005","unstructured":"Hunt SA  et al. (2005) ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154\u2013e235","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR52","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1136\/heart.85.4.e8","volume":"85","author":"C Berry","year":"2001","unstructured":"Berry C and McMurray JJ (2001) Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85: E8","journal-title":"Heart"},{"key":"BFncpcardio0914_CR53","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/110241501753361550","volume":"167","author":"IR Daniels","year":"2001","unstructured":"Daniels IR and Layer GT (2001) Gynaecomastia. Eur J Surg 167: 885\u2013892","journal-title":"Eur J Surg"},{"key":"BFncpcardio0914_CR54","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","volume":"111","author":"WS Weintraub","year":"2005","unstructured":"Weintraub WS  et al. (2005) Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 111: 1106\u20131113","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR55","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN and Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667\u20131675","journal-title":"N Engl J Med"},{"key":"BFncpcardio0914_CR56","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ  et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767\u2013771","journal-title":"Lancet"},{"key":"BFncpcardio0914_CR57","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"PM Mottram","year":"2004","unstructured":"Mottram PM  et al. (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110: 558\u2013565","journal-title":"Circulation"},{"key":"BFncpcardio0914_CR58","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","volume":"75","author":"G Klappacher","year":"1995","unstructured":"Klappacher G  et al. (1995) Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75: 913\u2013918","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR59","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0002-9149(99)80251-3","volume":"76","author":"NB Host","year":"1995","unstructured":"Host NB  et al. (1995) The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 76: 869\u2013873","journal-title":"Am J Cardiol"},{"key":"BFncpcardio0914_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/hy1101.099484","volume":"38","author":"F Zannad","year":"2001","unstructured":"Zannad F  et al. (2001) Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38: 1227\u20131232","journal-title":"Hypertension"},{"key":"BFncpcardio0914_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H  et al. (2002) Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40: 117\u2013123","journal-title":"Hypertension"},{"key":"BFncpcardio0914_CR62","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2005.01.014","volume":"45","author":"GS Francis","year":"2005","unstructured":"Francis GS and Tang WH (2005) Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol 45: 1249\u20131250","journal-title":"J Am Coll Cardiol"}],"container-title":["Nature Clinical Practice Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0914.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0914","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpcardio0914.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:42:05Z","timestamp":1684438925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpcardio0914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["BFncpcardio0914"],"URL":"https:\/\/doi.org\/10.1038\/ncpcardio0914","relation":{},"ISSN":["1743-4297","1743-4300"],"issn-type":[{"value":"1743-4297","type":"print"},{"value":"1743-4300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}